Comparative Pharmacology
Head-to-head clinical analysis: ADVIL LIQUI GELS versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL LIQUI GELS versus NAPROXEN SODIUM.
ADVIL LIQUI-GELS vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever.
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%.
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID